BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 364 filers reported holding BIO-TECHNE CORP in Q2 2019. The put-call ratio across all filers is 7.53 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $183,265,474 | +5.4% | 2,692,309 | +26.4% | 1.19% | +11.1% |
Q2 2023 | $173,913,450 | +24.0% | 2,130,509 | +12.7% | 1.07% | +21.3% |
Q1 2023 | $140,266,137 | -11.8% | 1,890,634 | -1.5% | 0.88% | -13.5% |
Q4 2022 | $159,109,626 | +15.8% | 1,919,759 | +296.6% | 1.02% | +8.8% |
Q3 2022 | $137,457,000 | -19.7% | 484,005 | -1.9% | 0.94% | -15.2% |
Q2 2022 | $171,100,000 | -20.6% | 493,595 | -0.8% | 1.11% | -0.9% |
Q1 2022 | $215,418,000 | -1.8% | 497,455 | +17.3% | 1.12% | +12.4% |
Q4 2021 | $219,326,000 | +15.4% | 423,950 | +8.1% | 0.99% | +9.1% |
Q3 2021 | $190,093,000 | -5.2% | 392,292 | -11.9% | 0.91% | -4.5% |
Q2 2021 | $200,474,000 | -10.1% | 445,240 | -23.8% | 0.95% | -17.8% |
Q1 2021 | $223,055,000 | -9.0% | 584,020 | -24.4% | 1.16% | -17.6% |
Q4 2020 | $245,199,000 | +6.2% | 772,160 | -17.1% | 1.41% | -10.3% |
Q3 2020 | $230,819,000 | -3.5% | 931,735 | +2.9% | 1.57% | -8.6% |
Q2 2020 | $239,179,000 | +15.1% | 905,740 | -17.4% | 1.72% | -8.3% |
Q1 2020 | $207,862,000 | +9.1% | 1,096,205 | +26.3% | 1.87% | +34.5% |
Q4 2019 | $190,463,000 | +17.0% | 867,675 | +4.3% | 1.39% | +4.0% |
Q3 2019 | $162,770,000 | +7.4% | 831,860 | +14.4% | 1.34% | +5.2% |
Q2 2019 | $151,613,000 | +6.0% | 727,195 | +1.0% | 1.27% | +2.1% |
Q1 2019 | $142,974,000 | +39.5% | 720,090 | +1.7% | 1.25% | +19.7% |
Q4 2018 | $102,476,000 | -15.5% | 708,100 | +19.2% | 1.04% | -3.2% |
Q3 2018 | $121,269,000 | +58.5% | 594,135 | +14.9% | 1.08% | +45.4% |
Q2 2018 | $76,497,000 | – | 517,045 | – | 0.74% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Ownership Capital B.V. | 972,263 | $308,742,000 | 4.35% |
Sandhill Capital Partners LLC | 138,864 | $44,096,000 | 4.03% |
STONE RUN CAPITAL, LLC | 27,350 | $8,685,000 | 3.45% |
DF DENT & CO INC | 925,823 | $293,995,000 | 3.42% |
Brown Capital Management | 1,498,233 | $475,764,000 | 3.29% |
MAIRS & POWER INC | 848,081 | $269,308,000 | 2.99% |
Summit Creek Advisors LLC | 64,179 | $20,380,000 | 2.62% |
GENEVA CAPITAL MANAGEMENT LLC | 402,958 | $127,959,000 | 2.17% |
Aristotle Atlantic Partners, LLC | 86,993 | $27,625,000 | 2.13% |
CROWN ADVISORS MANAGEMENT, INC. | 8,000 | $2,540,000 | 1.82% |